Joined Bio Appoints Erik Uribe as Head of Commercialization to Scale Biospecimen Sales
Biospecimen Industry Veteran to Drive Growth Strategy as Company Prepares to Launch Revolutionary Patient-Empowered Research Platform
BOSTON, MA – July 8, 2025 – Joined Bio, the AI-powered patient marketplace connecting life science organizations directly with research participants, today announced the appointment of Erik Uribe as Head of Commercialization. Erik brings over a decade of biospecimen and commercial strategy experience to lead Joined Bio's sales efforts and drive new research project acquisition as the company prepares for the launch of its groundbreaking patient platform.
In his new role, Erik will focus on sales strategy and business development, working to bring new research projects to Joined Bio utilizing both the company's established healthcare provider network and emerging direct-to-patient capabilities.
"Erik brings that rare combination of deep biospecimen expertise and the ability to translate complex requirements into clear researcher value," said Chris Ianelli, Co-CEO and Founder of Joined Bio. "At a time when traditional procurement is failing researchers, Erik knows how to demonstrate that our platform delivers results, not roadblocks."
Scaling Operations Following Strategic Acquisition
Erik's appointment comes on the heels of Joined Bio's acquisition of BioSample Connect, which expanded the company's healthcare provider network and operational capabilities. This strategic combination positions Joined Bio to scale biospecimen services immediately while developing its direct-to-patient marketplace platform that will eliminate traditional procurement bottlenecks.
The timing addresses critical industry pain points, with 85% of clinical research sites struggling to meet enrollment targets and biospecimen studies traditionally taking months to launch. Erik will focus on demonstrating how Joined Bio's dual approach reduces these timelines while expanding access to diverse patient populations.
"I'm excited to join Joined Bio at this pivotal moment," said Erik Uribe, Head of Commercialization. "The BioSample Connect acquisition combined with the company's innovative direct-to-patient vision creates immediate sales opportunities while positioning us at the forefront of industry transformation."
Prior to joining Joined Bio, Erik held senior commercialization roles at Discovery Life Sciences, iSpecimen, and Audubon Biosciences, where he was instrumental in growing their respective leadership positions in the biospecimen market. His experience spans inside sales, direct sales, sales operations, and company integrations, which uniquely positions him to execute Joined Bio's multi-faceted growth strategy while seamlessly integrating the newly acquired BioSample Connect operations.
About Joined Bio
Joined Bio is creating a revolutionary marketplace that reimagines how medical research connects with patient participation. The company's AI-powered platform securely analyzes electronic health records—with patient consent—to precisely match researchers with willing participants. Joined Bio also operates as a full-service biospecimen provider, sourcing samples through its established healthcare provider network. This dual approach enables rapid specimen collection and comprehensive data sharing while empowering patients to control their research involvement and earn compensation. For researchers, it means efficient access to ideal study candidates and their biospecimens, accelerating the pace of scientific discovery. For more information, visit www.joined.bio.
